We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics .

Download Mobile App





Novacyt's Two-Hour Coronavirus Test Gains FDA Emergency Use Approval

By HospiMedica International staff writers
Posted on 04 Apr 2020
Print article
Image: Novacyt’s real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test (Photo courtesy of Novacyt S.A.)
Image: Novacyt’s real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test (Photo courtesy of Novacyt S.A.)
Novacyt S.A. (Paris, France), a specialist in clinical diagnostics, has secured Emergency Use Authorization from the FDA for its fast and easily transportable COVID-19 test which was developed by Primerdesign, its molecular diagnostics division.

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialization, contract design and manufacturing. The company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, hematology and serology markets as do its global partners, which include major corporates.

Novacyt’s real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test detects viral genetic material, RNA, collected through a swab test of the nose or throat. The RNA is isolated from the sample and detected using qPCR, which amplifies genetic material. As compared to RNA detection methods used for confirming the virus in patients that takes up to four hours to deliver results and require specialized equipment, Novacyt’s test only detects the SARS-CoV-2 virus and produces results in less than two hours. The test is also designed to run on multiple instrument platforms used by clinical laboratories globally, ensuring that it can be used by a large number of clinicians. The company freeze-dries its kit reagents to ensure easy transport and storage, making its test suitable for tropical climates and low-resource settings.

Novacyt’s real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test is validated for use on the GenoXtract automated nucleic acid extraction device and associated extraction kits from Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Billerica, MA, USA). It is also under validation on Bruker’s new FluoroCycler XT PCR instrument, allowing Bruker to provide a full solution from automated extraction to result. Novacyt has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics.

Additionally, Novacyt has signed an agreement for certain contract manufacturing services with Yourgene Health Plc (Camberley, UK), an international molecular diagnostics group, which will provide support for the production of the COVID-19 diagnostic test.

Related Links:
Novacyt S.A.
Bruker Corporation
Yourgene Health Plc


Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Specimen Collection & Transport
New
X-Ray Meter
Cobia SENSE
Gold Supplier
Enteral Feeding Pump
SENTINELplus

Print article
Detecto

Channels

Critical Care

view channel
Image: An oil droplet (yellow) stabilized by temperature-sensitive microgels (green) in water (blue) (Photo courtesy of Marcel Rey)

Protected Droplets Could Revolutionize Methods of Targeting Medicines to Specific Body Locations

Emulsions are mixtures consisting of droplets suspended in a liquid where they don’t dissolve or mix. A common example is milk, where fat droplets, stabilized by milk proteins, are dispersed in water.... Read more

Surgical Techniques

view channel
Image: Smart lasers could eventually replace scalpels and saws in surgery (Photo courtesy of University of Basel)

Miniature Laser System Could Accurately Distinguish Tumors from Healthy Tissue

The integration of lasers into ophthalmology since the early 1990s marked a significant technological advancement, and since then, laser technology has expanded its reach into other medical fields.... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.